Erianin serves as an NFATc1 inhibitor to prevent breast cancer-induced osteoclastogenesis and bone destruction

Jiehuang Zheng(Guangdong Pharmaceutical University), Xiaojuan Li(Guilin Medical University)
Journal of Advanced Research
March 29, 2024
Cited by 13


Related Papers